Drug intelligence / Profile preview

SAN021

Development stage: Unknown
Lead developer: Santalis Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

SAN021 is a botanical drug product developed by Santalis Pharmaceuticals, Inc. It is a serum containing 10% East Indian Sandalwood Oil (EISO). It is being investigated for the topical treatment of mild-to-moderate plaque psoriasis in adult subjects. EISO exhibits anti-inflammatory, anti-proliferative, and anti-microbial properties, and has been shown to suppress chronic inflammatory chemokine/cytokine production.

Other names: SAN021 SerumSAN-021 SerumSAN 021 Serum

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)PDE4 (Phosphodiesterase 4A1)GM-CSF (Granulocyte-macrophage colony-stimulating factor)CCL2 (C-C motif chemokine 2)IL-17A (Interleukin-17A)IL-6 (Interleukin 6)IL1B (Interleukin-1 beta)CXCL5 (C-X-C motif chemokine ligand 5)

Beyond the preview

Go deeper on SAN021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAN021.

Explore the full profile